InMode Ltd. (INMD) fair value analysis
Nasdaq · Updated 2026-10-19
INMD price how computed
Forward Fair Value verdict
Fairly valuedINMD is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $14.16
- Sector
- Healthcare
- 12-month range
- $12.76–$16.62
- Market cap
- $815M
- From 52-week high
- -14.8%
- Shares outstanding
- 57.5M
- Rank in Healthcare by discount to fair value
- #66 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
InMode Ltd. is a medical device company that develops and markets minimally invasive aesthetic and surgical treatment systems. The company operates globally with a presence in multiple markets across North America, Europe, and other regions.
INMD currently ranks #66 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 6 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $815M
- P/E (trailing)
- 11x
- Revenue (TTM)
- $375M
- Net margin
- 20.7%
- EPS (TTM)
- $1.34
- Gross margin
- 74.8%
- Debt / equity
- 0.01
- Revenue growth (3-yr avg)
- -7.5%
- Shares outstanding
- 57.5M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Contracting
- 52-week position
- The lower-middle quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 39 · neutral
- 50-day average
- $14.65
- 200-day average
- $14.38
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-11 (pre-market)
- Last 8 quarters vs consensus
- 3 beat, 5 missed
- Quarter by quarter
- 2026-06 ▼ miss (-12.1%)
2026-03 ▼ miss (-16.7%)
2025-12 ▲ beat (+9.5%)
2025-09 ▼ miss (-2.9%)
2025-06 ▲ beat (+14.6%)
2025-03 ▼ miss (-11.4%)
2024-12 ▼ miss (-16.0%)
2024-09 ▲ beat (+14.8%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 0 buy · 5 hold · 0 sell (5 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $16.2
- Target vs last price
- +14.4%
What our data shows for INMD
- Our model validated 17 trailing price-to-earnings windows for INMD, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $12.76–$16.62.
- The 14-day relative strength index sits at a neutral 39.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for INMD
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent INMD news
TickrTrends' derived news-sentiment signal for INMD is currently leaning positive, computed from recent coverage.
- InMode: Reasonably Valued But With Too Much Drama (NASDAQ:INMD) (seekingalpha.com, 2026-09-16)
TickrTrends take: InMode operates in the Healthcare sector and is currently assessed as overvalued according to TickrTrends valuation metrics, which contrasts with the characterization in this headline that the company is reasonably valued. A reader focused on valuation should monitor whether the operational drama referenced in the headline translates into fundamental deterioration that might justify or challenge the current overvalued assessment. The divergence between this neutral valuation take and TickrTrends' overvalued verdict suggests investors should track both the company's financial metrics and the resolution of any internal challenges that could affect its true intrinsic value.
What people are saying
Follow the INMD conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — INMD is a Healthcare sector company that TickrTrends classifies as Fairly valued this week. The RSI zone improved from oversold to neutral, while the sector discount rank improved from number 91 to number 82. The valuation verdict shifted from Overvalued to Fairly valued.
- 2026-09-21 — INMD's technical indicators shifted this week as the Relative Strength Index moved from neutral territory into oversold conditions. This Healthcare sector stock maintains an overvalued valuation verdict according to TickrTrends' derived indicators. The oversold RSI reading suggests the stock has experienced recent selling pressure.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is INMD stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), INMD is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is INMD's TickrTrends verdict?
INMD's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does INMD compare to other Healthcare stocks?
INMD ranks #66 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is INMD overbought or oversold?
INMD's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does INMD report earnings next?
INMD's next earnings report is scheduled for 2026-11-11 (pre-market), per the published earnings calendar.
Does INMD usually beat earnings estimates?
Over its last 8 reported quarters INMD beat the consensus estimate 3 times and missed 5 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about INMD?
Of 5 analysts covering INMD, 0 rate it a buy, 5 a hold and 0 a sell - hold-leaning, with a consensus price target of $16.2 (+14.4% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
INMD vs A · INMD vs AVAH · INMD vs BVS · INMD vs ELV · INMD vs LFST